More recently, systematic genome-wide analyses of ADA against TNF inhibitors have been performed in a range of clinical contexts (11, 12); however, the only reported association with ADA to surpass the multiple-testing threshold for genome-wide significance is at HLA-DQA1*05 in individuals with inflammatory bowel disease (IBD) taking either infliximab or adalimumab (12). The gene discussed is TNF; the disease is inflammatory bowel disease.